where do we go from now, page-6

Hi Mike,

I must admit to being a little bearish on cce.

Just as a comparison, compare them to tis, who are valued about the same & are targeting a similar market, but maybe a bit more wound healing than skin healing.

tis:

1. Successful products on the market - no. (I'll be strict, like I was with cce. One of their partners has just started marketing a product, but will it sell?)

2. A deep product pipeline with late-stage candidates - yes

3. Drugs and candidates that target large or underserved markets - yes

4. Partnerships and marketing agreements with blue-chip drug manufacturers - yes

5. Research & development spending - yes

6. Enough cash to fund operations for two years - yes

7. Experienced management - yes

8. Favorable financial analysis - yes

7 out of 8, that's pretty good!